LCN2 and chronic kidney disease: Early identification of AKD through sensitive biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) could enable prompt intervention before eGFR decline is apparent and has shown promise for predicting near-term CKD signals after cisplatin.